Offringa R - Search Results

1

Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape.

Toes RE, Feltkamp MC, Ressing ME, Vierboom MP, Blom RJ, Brandt RM, Hartman M, Offringa R, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. Biochem Soc Trans. 1995 Aug;23(3):692-6. doi: 10.1042/bst0230692. Biochem Soc Trans. 1995. PMID: 8566445 Review. No abstract available.

2

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7855-60. doi: 10.1073/pnas.93.15.7855. Proc Natl Acad Sci U S A. 1996. PMID: 8755566 Free PMC article.

3

Peptide-based cancer vaccines.

Melief CJ, Offringa R, Toes RE, Kast WM. Melief CJ, et al. Among authors: offringa r. Curr Opin Immunol. 1996 Oct;8(5):651-7. doi: 10.1016/s0952-7915(96)80081-1. Curr Opin Immunol. 1996. PMID: 8902390 Review.

4

Activation or frustration of anti-tumor responses by T-cell-based immune modulation.

Toes RE, Schoenberger SP, van der Voort EI, Kast WM, Hoeben RC, Melief CJ, Offringa R. Toes RE, et al. Among authors: offringa r. Semin Immunol. 1997 Oct;9(5):323-7. doi: 10.1006/smim.1997.0088. Semin Immunol. 1997. PMID: 9327527 Review.

5

Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity.

Ressing ME, Offringa R, Toes RE, Ossendorp F, de Jong JH, Brandt RM, Kast WM, Melief CJ. Ressing ME, et al. Among authors: offringa r. Immunotechnology. 1996 Nov;2(4):241-51. doi: 10.1016/s1380-2933(96)00057-7. Immunotechnology. 1996. PMID: 9373306 Review.

6

Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma.

Ressing ME, de Jong JH, Brandt RM, Drijfhout JW, Benckhuijsen WE, Schreuder GM, Offringa R, Kast WM, Melief CJ. Ressing ME, et al. Among authors: offringa r. Eur J Immunol. 1999 Apr;29(4):1292-303. doi: 10.1002/(SICI)1521-4141(199904)29:04<1292::AID-IMMU1292>3.0.CO;2-6. Eur J Immunol. 1999. PMID: 10229097 Free article.

7

Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.

Melief CJ, Van Der Burg SH, Toes RE, Ossendorp F, Offringa R. Melief CJ, et al. Among authors: offringa r. Immunol Rev. 2002 Oct;188:177-82. doi: 10.1034/j.1600-065x.2002.18816.x. Immunol Rev. 2002. PMID: 12445291

8

Design and development of synthetic peptide vaccines: past, present and future.

Bijker MS, Melief CJ, Offringa R, van der Burg SH. Bijker MS, et al. Among authors: offringa r. Expert Rev Vaccines. 2007 Aug;6(4):591-603. doi: 10.1586/14760584.6.4.591. Expert Rev Vaccines. 2007. PMID: 17669012 Free article. Review.

9

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.

Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. J Immunol. 1995 Apr 1;154(7):3396-405. J Immunol. 1995. PMID: 7534797

10

Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.

Toes RE, Offringa R, Feltkamp MC, Visseren MJ, Schoenberger SP, Melief CJ, Kast WM. Toes RE, et al. Among authors: offringa r. Behring Inst Mitt. 1994 Jul;(94):72-86. Behring Inst Mitt. 1994. PMID: 7998917 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

267 results

Search Page

Filters